You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
信達生物(01801.HK)一季度總產品收入超10億元 商業化管道已覆蓋全國
格隆匯 04-28 18:44

格隆匯4月28日丨信達生物(01801.HK)公吿,截至2022年第一季度,公司已取得七款產品獲批,包括:達伯舒(信迪利單抗注射液)、達攸同(貝伐珠單抗生物類似藥)、蘇立信(阿達木單抗生物類似藥)達伯華(利妥昔單抗生物類似藥)、達伯坦(佩米替尼片)、耐立克(奧雷巴替尼)和希冉擇(雷莫西尤單抗)。

於2022年第一季度,公司共取得總產品收入超人民幣10億元,相比去年同期持續保持雙位數的快速增長,主要來自於已獲批商業化產品組合的持續放量增長。達伯舒(信迪利單抗注射液)新增三項一線大適應症進入新版國家醫保目錄,其在PD-1市場的領先地位明確,患者使用率及銷量持續增長;此外,其它產品按年增長強勁,收入貢獻佔比持續擴大,市場覆蓋及准入繼續提升。公司商業化產品組合愈加豐富,協同價值凸顯,為產品收入的持續增長打下堅實基礎。

公司已建立較為成熟完備的商業化平台,包括一支由近3,000名經驗豐富的行銷及銷售專業人員組成的商業化團隊,專責推動產品組合進入市場及開展學術推廣,廣闊的商業化管道覆蓋全國,保障實現創新管線的產品價值。

公司相信,令人鼓舞的產品收入的快速增長展現了公司商業化產品的市場潛力及作為優質生產商的能力。公司已建立起一條擁有涵蓋癌症、代謝、自身免疫疾病等主要治療領域的32個新藥品種的創新產品管線,包括7個在中國獲批產品,1個品種在國家藥品監督管理局審評中,5個品種處於臨牀III期或關鍵性臨牀研究,19款候選產品正在進行前期臨牀開發。公司相信,其豐厚的創新資產管線具有廣闊的市場潛力,為公司長期全球創新業務發展提供堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account